Thanks for the post bfw, interesting to see that heart disease and kidney disease are at the top of the list of concern. Also interesting that AstraZeneca are early big pharma entrants in China.

I still think AZ could be one to watch as far as an RVX takeout goes. The extra patent life the Apabetalone/Crestor patent would present to AZ has got to be looming large on someone’s radar at AZ and given the large and growing number of government insured Chinese the monetary metrics of a relatively cheap drug have got to be a huge attraction both from a corporate as well as government perspective.